Identification

Name
Icosapent
Accession Number
DB00159  (NUTR00024)
Type
Small Molecule
Groups
Approved, Nutraceutical
Description

Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.

Structure
Thumb
Synonyms
  • (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid
  • (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate
  • (5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid
  • (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
  • (all-Z)-5,8,11,14,17-eicosapentaenoic acid
  • 5,8,11,14,17-eicosapentaenoic acid
  • 5,8,11,14,17-Icosapentaenoic acid
  • all-cis-5,8,11,14,17-eicosapentaenoic acid
  • all-cis-5,8,11,14,17-icosapentaenoic acid
  • all-cis-icosa-5,8,11,14,17-pentaenoic acid
  • cis-5,8,11,14,17-eicosapentaenoic acid
  • cis-5,8,11,14,17-EPA
  • cis-delta(5,8,11,14,17)-Eicosapentaenoic acid
  • Eicosapentaenoic acid
  • EPA
  • Icosapentaenoic acid
  • Icosapento
  • Icosapentum
  • Timnodonic acid
External IDs
EPA 45G
Product Ingredients
IngredientUNIICASInChI Key
Icosapent sodium5PXN91KPRO73167-03-0RBZYGQJEMWGTOH-RSDXMDNYSA-M
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
HerbalifelineIcosapent (119 mg)CapsuleOralHerbalife International Of Luxembourg S À R L2004-07-192009-07-21Canada
Natelle OneIcosapent (.625 mg/1) + Calcium phosphate, tribasic (100 mg/1) + Doconexent (250 mg/1) + Folic Acid (1 mg/1) + Ferrous fumarate (27 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Vitamin C (30 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralAzur Pharma, Inc.2009-11-09Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Animi-3Icosapent (35 mg/1) + Cholecalciferol (1000 [iU]/1) + Cyanocobalamin (500 ug/1) + Doconexent (250 mg/1) + Folic Acid (1 mg/1) + Omega-3 fatty acids (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) + Soy sterol (200 mg/1)CapsuleOralPbm Pharmaceuticals Inc.2011-06-01Not applicableUs
Animi-3 with Vitamin DIcosapent (35 mg/1) + Cholecalciferol (1000 [iU]/1) + Cyanocobalamin (500 ug/1) + Doconexent (250 mg/1) + Folic Acid (1 mg/1) + Omega-3 fatty acids (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) + Soy sterol (200 mg/1)CapsuleOralPbm Pharmaceuticals Inc.2011-06-01Not applicableUs
CitraNatal AssureIcosapent + DoconexentKitMission Pharmacal2014-04-30Not applicableUs
Folcaps Care OneIcosapent (100 mg/1) + Alpha-Linolenic Acid (50 mg/1) + Biotin (300 mg/1) + Calcium Carbonate (100 mg/1) + Calcium threonate (1 mg/1) + Cholecalciferol (800 [iU]/1) + D-alpha-Tocopherol acetate (15 [iU]/1) + Doconexent (350 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iodine (150 ug/1) + Iron (27 mg/1) + Magnesium (50 mg/1) + Nicotinamide (10 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.5 mg/1) + Calcium ascorbate (24 mg/1) + Zinc (5 mg/1)Capsule, gelatin coatedOralMidlothian Laboratories2009-05-012018-01-10Us
Folcaps Omega-3Icosapent (40 mg/1) + Alpha-Linolenic Acid (30 mg/1) + Calcium (150 mg/1) + Calcium threonate (1 mg/1) + Cholecalciferol (170 [iU]/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Doconexent (260 mg/1) + Ferrous asparto glycinate (7 mg/1) + Folic Acid (1 mg/1) + Iron (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Calcium ascorbate (24 mg/1)Capsule, gelatin coatedOralMidlothian Laboratories2011-01-032017-12-22Us
Gesticare DHAIcosapent + Calcium Carbonate + Cholecalciferol + Choline bitartrate + Cyanocobalamin + D-alpha-Tocopherol acetate + Doconexent + Folic Acid + Ferrous fumarate + Niacin + Potassium Iodide + Pyridoxine hydrochloride + Riboflavin + Thiamine mononitrate + Vitamin C + Zinc oxideKitJazz Pharmaceuticals Commercial Corp.2008-10-01Not applicableUs
Natelle OneIcosapent (.625 mg/1) + Calcium phosphate, tribasic (102 mg/1) + Doconexent (250 mg/1) + Folic Acid (1 mg/1) + Ferrous fumarate (28 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Vitamin C (30 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralJazz Pharmaceuticals Commercial Corp.2010-06-11Not applicableUs
Natelle OneIcosapent (.625 mg/1) + Calcium (102 mg/1) + Doconexent (250 mg/1) + Folic Acid (1 mg/1) + Iron (28 mg/1) + Pyridoxine (25 mg/1) + Vitamin C (30 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralMeda Pharmaceuticals Ltd2015-02-01Not applicableUs
PNV-OmegaIcosapent (40 mg/1) + Biotin (250 ug/1) + Calcium Carbonate (140 mg/1) + Cholecalciferol (200 [iU]/1) + Cyanocobalamin (12 ug/1) + Doconexent (300 mg/1) + Folic Acid (1 mg/1) + Ferrous fumarate (28 mg/1) + Magnesium oxide (45 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine (25 mg/1) + Vitamin C (85 mg/1) + Vitamin E (10 [iU]/1)Capsule, gelatin coatedOralAcella Pharmaceuticals, LLC2010-07-28Not applicableUs
Prenate EssentialIcosapent (40 mg/1) + 5-methyltetrahydrofolic acid (600 ug/1) + Biotin (280 ug/1) + Cholecalciferol (220 [iU]/1) + Cyanocobalamin (13 ug/1) + Doconexent (300 mg/1) + Ferrous asparto glycinate (18 mg/1) + Folic Acid (400 ug/1) + Calcium formate (155 mg/1) + Magnesium oxide (50 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (26 mg/1) + Vitamin C (90 mg/1) + Vitamin E (10 [iU]/1)Capsule, gelatin coatedOralAvion Pharmaceuticals, Llc2014-07-18Not applicableUs
Categories
UNII
AAN7QOV9EA
CAS number
10417-94-4
Weight
Average: 302.451
Monoisotopic: 302.224580204
Chemical Formula
C20H30O2
InChI Key
JAZBEHYOTPTENJ-JLNKQSITSA-N
InChI
InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
IUPAC Name
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
SMILES
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O

Pharmacology

Indication

EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.

Pharmacodynamics

Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.

Mechanism of action

The anti-inflammatory, antithrombotic and immunomodulatory actions of EPA is probably due to its role in eicosanoid physiology and biochemistry. Most eicosanoids are produced by the metabolism of omega-3 fatty acids, specifically, arachidonic acid. These eicosanoids, leukotriene B4 (LTB4) and thromboxane A2 (TXA2) stimulate leukocyte chemotaxis, platelet aggregation and vasoconstriction. They are thrombogenic and artherogenic. On the other hand, EPA is metabolized to leukotriene B5 (LTB5) and thromboxane A3 (TXA3), which are eicosanoids that promote vasodilation, inhibit platelet aggregation and leukocyte chemotaxis and are anti-artherogenic and anti-thrombotic. The triglyceride-lowering effect of EPA results from inhibition of lipogenesis and stimulation of fatty acid oxidation. Fatty acid oxidation of EPA occurs mainly in the mitochondria. EPA is a substrate for Prostaglandin-endoperoxide synthase 1 and 2. It also appears to affect the function and bind to the Carbohydrate responsive element binding protein (ChREBP) and to a fatty acid receptor (G-coupled receptor) known as GP40.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
APeroxisome proliferator-activated receptor gamma
agonist
Human
APeroxisome proliferator-activated receptor delta
agonist
Human
UFatty acid desaturase 1
agonist
Human
ULong-chain-fatty-acid--CoA ligase 4
inducer
Human
ULong-chain-fatty-acid--CoA ligase 3
inducer
Human
AFree fatty acid receptor 1
agonist
Human
ASodium/calcium exchanger 1
inhibitor
Human
UTransient receptor potential cation channel subfamily V member 1
inducer
Human
UPeroxisome proliferator-activated receptor alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Alpha Linolenic Acid and Linoleic Acid MetabolismMetabolic
Alpha Linolenic Acid and Linoleic Acid MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Icosapent.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Icosapent.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Icosapent.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Icosapent.Experimental, Illicit
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Icosapent.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Icosapent.Approved, Experimental, Investigational
AcenocoumarolIcosapent may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Icosapent.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Icosapent.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Icosapent.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Icosapent.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Icosapent.Experimental, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Icosapent.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Icosapent.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Icosapent.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Icosapent.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Icosapent.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Icosapent.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Icosapent.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Icosapent.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Icosapent.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Icosapent.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Icosapent.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Icosapent.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Icosapent.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Icosapent.Approved, Investigational
BazedoxifeneIcosapent may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Icosapent.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Icosapent.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Icosapent.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Icosapent.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Icosapent.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Icosapent.Approved, Vet Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Icosapent.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Icosapent.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Icosapent.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Icosapent.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Icosapent.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Icosapent.Experimental
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Icosapent.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Icosapent.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Icosapent.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Icosapent.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Icosapent.Approved, Investigational, Vet Approved
ChlorotrianiseneIcosapent may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icosapent.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Icosapent.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Icosapent.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Icosapent.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Icosapent.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Icosapent.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Icosapent.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Icosapent.Approved
ClorindioneIcosapent may increase the anticoagulant activities of Clorindione.Experimental
Conjugated estrogensIcosapent may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Icosapent.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Icosapent.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Icosapent.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Icosapent.Approved, Investigational
DaidzeinIcosapent may increase the thrombogenic activities of Daidzein.Experimental
DapoxetineDapoxetine may increase the antiplatelet activities of Icosapent.Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Icosapent.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Icosapent.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Icosapent.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Icosapent.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Icosapent.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Icosapent.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Icosapent.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Icosapent.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Icosapent.Approved, Vet Approved
DicoumarolIcosapent may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolIcosapent may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolIcosapent may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Icosapent.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Icosapent.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Icosapent.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Icosapent.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Icosapent.Approved
DiphenadioneIcosapent may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Icosapent.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Icosapent.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Icosapent.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Icosapent.Investigational
EpimestrolIcosapent may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Icosapent.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Icosapent.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Icosapent.Approved
EquolIcosapent may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Icosapent.Approved, Investigational
EstradiolIcosapent may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateIcosapent may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateIcosapent may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateIcosapent may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolIcosapent may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedIcosapent may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneIcosapent may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Icosapent.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Icosapent.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Icosapent.Experimental
Ethinyl EstradiolIcosapent may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateIcosapent may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Icosapent.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Icosapent.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Icosapent.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Icosapent.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Icosapent.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Icosapent.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Icosapent.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Icosapent.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Icosapent.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Icosapent.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Icosapent.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Icosapent.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Icosapent.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Icosapent.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Icosapent.Approved, Investigational
FluindioneIcosapent may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Icosapent.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Icosapent.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Icosapent.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Icosapent.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Icosapent.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Icosapent.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Icosapent.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Icosapent.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Icosapent.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Icosapent.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Icosapent.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Icosapent.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Icosapent.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Icosapent.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Icosapent.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Icosapent.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Icosapent.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Icosapent.Approved, Investigational, Withdrawn
GenisteinIcosapent may increase the thrombogenic activities of Genistein.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Icosapent.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Icosapent.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Icosapent.Investigational
HexestrolIcosapent may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Icosapent.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Icosapent.Approved, Vet Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Icosapent.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Icosapent.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Icosapent.Approved, Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Icosapent.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Icosapent.Investigational, Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Icosapent.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Icosapent.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Icosapent.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Icosapent.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Icosapent.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Icosapent.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Icosapent.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Icosapent.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Icosapent.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Icosapent.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Icosapent.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Icosapent.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Icosapent.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Icosapent.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Icosapent.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Icosapent.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icosapent.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Icosapent.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Icosapent.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icosapent.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Icosapent.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icosapent.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Icosapent.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Icosapent.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Icosapent.Approved
MestranolIcosapent may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Icosapent.Approved, Investigational, Withdrawn
MethallenestrilIcosapent may increase the thrombogenic activities of Methallenestril.Experimental
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Icosapent.Approved, Vet Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Icosapent.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Icosapent.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Icosapent.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Icosapent.Approved, Vet Approved
MoxestrolIcosapent may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icosapent.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icosapent.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Icosapent.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Icosapent.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Icosapent.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Icosapent.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Icosapent.Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Icosapent.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Icosapent.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Icosapent.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Icosapent.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Icosapent.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Icosapent.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Icosapent.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icosapent.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Icosapent.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Icosapent.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Icosapent.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icosapent.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Icosapent.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Icosapent.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Icosapent.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Icosapent.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Icosapent.Approved, Investigational
PhenindioneIcosapent may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonIcosapent may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icosapent.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Icosapent.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Icosapent.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Icosapent.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Icosapent.Experimental
Polyestradiol phosphateIcosapent may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Icosapent.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Icosapent.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Icosapent.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Icosapent.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Icosapent.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Icosapent.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Icosapent.Approved, Experimental, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Icosapent.Experimental
PromestrieneIcosapent may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Icosapent.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Icosapent.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Icosapent.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Icosapent.Investigational
QuinestrolIcosapent may increase the thrombogenic activities of Quinestrol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Icosapent.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Icosapent.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Icosapent.Approved, Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Icosapent.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Icosapent.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Icosapent.Approved
SecoisolariciresinolIcosapent may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Icosapent.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Icosapent.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Icosapent.Investigational
SertralineSertraline may increase the antiplatelet activities of Icosapent.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Icosapent.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icosapent.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Icosapent.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Icosapent.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Icosapent.Experimental
Synthetic Conjugated Estrogens, AIcosapent may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BIcosapent may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Icosapent.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Icosapent.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Icosapent.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Icosapent.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Icosapent.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Icosapent.Approved
TiboloneIcosapent may increase the thrombogenic activities of Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Icosapent.Investigational
TioclomarolIcosapent may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Icosapent.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Icosapent.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Icosapent.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Icosapent.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Icosapent.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Icosapent.Experimental
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Icosapent.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Icosapent.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Icosapent.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Icosapent.Approved
WarfarinIcosapent may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Icosapent.Approved, Investigational
ZeranolIcosapent may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Icosapent.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Icosapent.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Icosapent.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Akira Seto, Shoko Yamashita, "Method of preparing fatty acid composition containing high concentration of eicosapentaenoic acid." U.S. Patent US4615839, issued March, 1983.

US4615839
General References
  1. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN: Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16. [PubMed:21683321]
External Links
Human Metabolome Database
HMDB0001999
KEGG Drug
D08061
KEGG Compound
C06428
PubChem Compound
446284
PubChem Substance
46506267
ChemSpider
393682
BindingDB
50242349
ChEBI
28364
ChEMBL
CHEMBL460026
Therapeutic Targets Database
DAP000969
PharmGKB
PA164746077
IUPHAR
3362
Guide to Pharmacology
GtP Drug Page
HET
EPA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Eicosapentaenoic_acid
PDB Entries
1igx / 3gwx / 3hs6 / 5m0o
FDA label
Download (173 KB)
MSDS
Download (23.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentMajor Depressive Disorder in Pregnancy2
1Active Not RecruitingTreatmentNeoplasms, Breast / Stage 0 Breast Carcinoma / Stage I Breast Carcinoma / Stage II Breast Carcinoma / Stage III Breast Carcinoma1
1CompletedTreatmentHealthy Volunteers1
2CompletedBasic ScienceAdipose Tissue Inflammation / Obesity, Morbid1
2CompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Respiratory Distress Syndrome, Adult1
2CompletedTreatmentBipolar Disorder (BD) / Coronary Artery Disease / Major Depressive Disorder (MDD) / Schizoaffective Disorders / Schizophrenic Disorders1
2CompletedTreatmentSubstance-Related Disorders1
2, 3CompletedPreventionFamilial Adenomatous Polyposis Coli / FAP1
2, 3CompletedTreatmentAbstinence Syndrome / Behavior, Addictive1
2, 3CompletedTreatmentAdenomatous Polyps1
2, 3CompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
2, 3RecruitingTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Inflammatory Reaction / Major Depressive Disorder (MDD)1
3CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Cataracts1
3CompletedTreatmentCardiovascular Disease (CVD) / Inflammatory Reaction1
3CompletedTreatmentCoronary Heart Disease (CHD) / Myocardial Infarction1
3CompletedTreatmentHypertriglyceridemias1
3RecruitingTreatmentTransplantation, Kidney1
3TerminatedPreventionCoronary Artery Disease / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentCancer treatment / Colorectal Cancers / Malignant Neoplasm of Stomach1
3Unknown StatusTreatmentRheumatoid Arthritis1
4Active Not RecruitingPreventionMalignant Neoplasm of Colon1
4Active Not RecruitingTreatmentObesity, Morbid1
4CompletedOtherBioavailability1
4CompletedTreatmentCoronary Artery Disease Progression1
4CompletedTreatmentDyskinesias / Schizophrenic Disorders1
4RecruitingTreatmentBMI >30 kg/m2 / Esophagus, Barrett1
4Unknown StatusTreatmentArrythmias / Coronary Artery Disease1
Not AvailableActive Not RecruitingPreventionAutoimmune Diseases / Knee Pain Chronic / Osteoarthritis (OA) / Rheumatoid Arthritis / Systemic Inflammatory Process1
Not AvailableActive Not RecruitingPreventionType 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCancer Cachexia1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableEnrolling by InvitationPreventionAdiposity1
Not AvailableRecruitingBasic ScienceHyperlipidemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • V Sab Medical Labs Inc.
Dosage forms
FormRouteStrength
CapsuleOral
Kit
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
logP6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000289 mg/mLALOGPS
logP6.53ALOGPS
logP6.23ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)4.82ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity101.07 m3·mol-1ChemAxon
Polarizability35.93 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9896
Blood Brain Barrier+0.9314
Caco-2 permeable+0.7735
P-glycoprotein substrateNon-substrate0.6766
P-glycoprotein inhibitor INon-inhibitor0.9499
P-glycoprotein inhibitor IINon-inhibitor0.9025
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.7735
CYP450 2D6 substrateNon-substrate0.9081
CYP450 3A4 substrateNon-substrate0.6884
CYP450 1A2 substrateInhibitor0.6915
CYP450 2C9 inhibitorNon-inhibitor0.8798
CYP450 2D6 inhibitorNon-inhibitor0.9631
CYP450 2C19 inhibitorNon-inhibitor0.9638
CYP450 3A4 inhibitorNon-inhibitor0.9465
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9426
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6502
BiodegradationReady biodegradable0.7808
Rat acute toxicity1.4499 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8818
hERG inhibition (predictor II)Non-inhibitor0.9315
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-004l-9700000000-09ea61ed836b88205028
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-004l-9700000000-09ea61ed836b88205028
Mass Spectrum (Electron Ionization)MSsplash10-05ox-9400000000-567226e93d65502352cd
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-0029000000-02c67e3601df249d2476

Taxonomy

Description
This compound belongs to the class of organic compounds known as long-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Long-chain fatty acids
Alternative Parents
Unsaturated fatty acids / Straight chain fatty acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Long-chain fatty acid / Unsaturated fatty acid / Straight chain fatty acid / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
omega-3 fatty acid, icosapentaenoic acid (CHEBI:28364) / Unsaturated fatty acids, Polyunsaturated fatty acids, Liner triterpenes (C06428) / Unsaturated fatty acids (LMFA01030759)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1. [PubMed:12562875]
  2. Ait-Said F, Elalamy I, Werts C, Gomard MT, Jacquemin C, Couetil JP, Hatmi M: Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta. 2003 Feb 20;1631(1):77-84. [PubMed:12573452]
  3. Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M: Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005 Sep;99(1):113-6. Epub 2005 Sep 1. [PubMed:16141635]
  4. Das UN: Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India. 2005 Jul;53:623-7. [PubMed:16190133]
  5. Chene G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M, Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta. 2007 May;1771(5):576-89. Epub 2007 Mar 16. [PubMed:17459764]
  6. Vecchio AJ, Simmons DM, Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. doi: 10.1074/jbc.M110.119867. Epub 2010 May 12. [PubMed:20463020]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Malkowski MG, Thuresson ED, Lakkides KM, Rieke CJ, Micielli R, Smith WL, Garavito RM: Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem. 2001 Oct 5;276(40):37547-55. Epub 2001 Jul 27. [PubMed:11477109]
  2. Machida T, Hiramatsu M, Hamaue N, Minami M, Hirafuji M: Docosahexaenoic acid enhances cyclooxygenase-2 induction by facilitating p44/42, but not p38, mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Pharmacol Sci. 2005 Sep;99(1):113-6. Epub 2005 Sep 1. [PubMed:16141635]
  3. Das UN: COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit. 2005 Jul;11(7):RA233-7. Epub 2005 Jun 29. [PubMed:15990700]
  4. Das UN: Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India. 2005 Jul;53:623-7. [PubMed:16190133]
  5. Yang P, Chan D, Felix E, Cartwright C, Menter DG, Madden T, Klein RD, Fischer SM, Newman RA: Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res. 2004 Jun;45(6):1030-9. Epub 2004 Mar 1. [PubMed:14993240]
  6. Vecchio AJ, Simmons DM, Malkowski MG: Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. doi: 10.1074/jbc.M110.119867. Epub 2010 May 12. [PubMed:20463020]
  7. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, Hwang DH: Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1. [PubMed:12562875]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H: Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res. 2002 Jun;10(6):518-25. [PubMed:12055328]
  2. Selvaraj RK, Klasing KC: Lutein and eicosapentaenoic acid interact to modify iNOS mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines. J Nutr. 2006 Jun;136(6):1610-6. [PubMed:16702329]
  3. Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A: Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J Mol Graph Model. 2001;19(6):536-42, 598-600. [PubMed:11552681]
  4. Horia E, Watkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis. 2007 Apr;28(4):809-15. Epub 2006 Oct 19. [PubMed:17052999]
  5. Ramakers JD, Mensink RP, Schaart G, Plat J: Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids. 2007 Aug;42(8):687-98. Epub 2007 Jul 3. [PubMed:17610002]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A: Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. J Mol Graph Model. 2001;19(6):536-42, 598-600. [PubMed:11552681]
  2. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell. 1999 Mar;3(3):397-403. [PubMed:10198642]
  3. Kondo H, Misaki R, Gelman L, Watabe S: Ligand-dependent transcriptional activities of four torafugu pufferfish Takifugu rubripes peroxisome proliferator-activated receptors. Gen Comp Endocrinol. 2007 Oct-Dec;154(1-3):120-7. Epub 2007 Jun 12. [PubMed:17632107]
  4. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998 May 19;246(2):370-4. [PubMed:9610365]
  5. Caldari-Torres C, Rodriguez-Sallaberry C, Greene ES, Badinga L: Differential effects of n-3 and n-6 fatty acids on prostaglandin F2alpha production by bovine endometrial cells. J Dairy Sci. 2006 Mar;89(3):971-7. [PubMed:16507691]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Oxidoreductase activity
Specific Function
Isoform 2 does not exhibit any catalytic activity toward 20:3n-6, but it may enhance FADS2 activity (By similarity). Isoform 1 is a component of a lipid metabolic pathway that catalyzes biosynthesi...
Gene Name
FADS1
Uniprot ID
O60427
Uniprot Name
Fatty acid desaturase 1
Molecular Weight
51963.945 Da
References
  1. Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH: Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr. 2000 Aug;130(8):1925-31. [PubMed:10917903]
  2. Navarro E, Esteve M, Olive A, Klaassen J, Cabre E, Tena X, Fernandez-Banares F, Pastor C, Gassull MA: Abnormal fatty acid pattern in rheumatoid arthritis. A rationale for treatment with marine and botanical lipids. J Rheumatol. 2000 Feb;27(2):298-303. [PubMed:10685788]
  3. Engler MM, Bellenger-Germain SH, Engler MB, Narce MM, Poisson JP: Dietary docosahexaenoic acid affects stearic acid desaturation in spontaneously hypertensive rats. Lipids. 2000 Sep;35(9):1011-5. [PubMed:11026622]
  4. Chavali SR, Zhong WW, Forse RA: Dietary alpha-linolenic acid increases TNF-alpha, and decreases IL-6, IL-10 in response to LPS: effects of sesamin on the delta-5 desaturation of omega6 and omega3 fatty acids in mice. Prostaglandins Leukot Essent Fatty Acids. 1998 Mar;58(3):185-91. [PubMed:9610840]
  5. Watts JL, Browse J: Isolation and characterization of a Delta 5-fatty acid desaturase from Caenorhabditis elegans. Arch Biochem Biophys. 1999 Feb 1;362(1):175-82. [PubMed:9917342]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Very long-chain fatty acid-coa ligase activity
Specific Function
Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.
Gene Name
ACSL4
Uniprot ID
O60488
Uniprot Name
Long-chain-fatty-acid--CoA ligase 4
Molecular Weight
79187.38 Da
References
  1. Heimli H, Hollung K, Drevon CA: Eicosapentaenoic acid-induced apoptosis depends on acyl CoA-synthetase. Lipids. 2003 Mar;38(3):263-8. [PubMed:12784866]
  2. Covault J, Pettinati H, Moak D, Mueller T, Kranzler HR: Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. Am J Med Genet B Neuropsychiatr Genet. 2004 May 15;127B(1):42-7. [PubMed:15108178]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Protein kinase binding
Specific Function
Acyl-CoA synthetases (ACSL) activates long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL3 mediates hepatic lipogenesis (By similarity). Preferent...
Gene Name
ACSL3
Uniprot ID
O95573
Uniprot Name
Long-chain-fatty-acid--CoA ligase 3
Molecular Weight
80419.415 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Lipid binding
Specific Function
G-protein coupled receptor for medium and long chain saturated and unsaturated fatty acids that plays an important role in glucose homeostasis. Fatty acid binding increases glucose-stimulated insul...
Gene Name
FFAR1
Uniprot ID
O14842
Uniprot Name
Free fatty acid receptor 1
Molecular Weight
31456.645 Da
References
  1. Itoh Y, Hinuma S: GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res. 2005 Oct;33(2):171-3. Epub 2005 Oct 6. [PubMed:16214394]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ion channel binding
Specific Function
Mediates the exchange of one Ca(2+) ion against three to four Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellul...
Gene Name
SLC8A1
Uniprot ID
P32418
Uniprot Name
Sodium/calcium exchanger 1
Molecular Weight
108546.06 Da
References
  1. Xiao YF, Ke Q, Chen Y, Morgan JP, Leaf A: Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun. 2004 Aug 13;321(1):116-23. [PubMed:15358223]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Transmembrane signaling receptor activity
Specific Function
Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular aci...
Gene Name
TRPV1
Uniprot ID
Q8NER1
Uniprot Name
Transient receptor potential cation channel subfamily V member 1
Molecular Weight
94955.33 Da
References
  1. Matta JA, Miyares RL, Ahern GP: TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J Physiol. 2007 Jan 15;578(Pt 2):397-411. Epub 2006 Oct 12. [PubMed:17038422]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T: Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun. 1999 Jul 14;260(3):609-13. [PubMed:10403814]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transporter activity
Specific Function
B-FABP could be involved in the transport of a so far unknown hydrophobic ligand with potential morphogenic activity during CNS development. It is required for the establishment of the radial glial...
Gene Name
FABP7
Uniprot ID
O15540
Uniprot Name
Fatty acid-binding protein, brain
Molecular Weight
14888.855 Da
References
  1. Balendiran GK, Schnutgen F, Scapin G, Borchers T, Xhong N, Lim K, Godbout R, Spener F, Sacchettini JC: Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. J Biol Chem. 2000 Sep 1;275(35):27045-54. [PubMed:10854433]
  2. Liu YE, Pu W, Wang J, Kang JX, Shi YE: Activation of Stat5 and induction of a pregnancy-like mammary gland differentiation by eicosapentaenoic and docosapentaenoic omega-3 fatty acids. FEBS J. 2007 Jul;274(13):3351-62. Epub 2007 Jun 5. [PubMed:17547694]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Pavicevic ID, Jovanovic VB, Takic MM, Penezic AZ, Acimovic JM, Mandic LM: Fatty acids binding to human serum albumin: Changes of reactivity and glycation level of Cysteine-34 free thiol group with methylglyoxal. Chem Biol Interact. 2014 Dec 5;224:42-50. doi: 10.1016/j.cbi.2014.10.008. Epub 2014 Oct 17. [PubMed:25451573]

Drug created on June 13, 2005 07:24 / Updated on June 23, 2018 21:10